Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coeptis Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COEP
Over the counter
2834
https://coeptistx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coeptis Therapeutics Inc
Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors
- May 17th, 2022 11:00 am
Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement
- Apr 19th, 2022 11:00 am
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
- Apr 13th, 2022 8:05 pm
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma
- Apr 13th, 2022 11:00 am
Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development
- Jan 20th, 2022 1:00 pm
Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers
- Aug 19th, 2021 12:30 pm
Scroll